The 3′ region of human papillomavirus type 16 early mRNAs decrease expression

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Vinther, Jeppe ^a,b   Rosenstierne, Maiken W ^a   Kristiansen, Karen ^a,c   Norrild, Bodil ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VIRUS RNA;

3' UNTRANSLATED REGION; ARTICLE; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR CLONING; NONHUMAN; NORTHERN BLOTTING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; VIRUS GENOME; CELL LINE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS;

3' UNTRANSLATED REGIONS; CELL LINE; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; RNA, VIRAL;

EID: 27844520404     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-83     Document Type: Article

References (40)

1. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
2. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001, 357:1831-1836.
3. Vinther J, Norrild B: Clearance of cervical human papillomavirus infections. Int J Cancer 2003, 104:255-256.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
5. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
6. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92:690-698.
7. Chien WM, Noya F, H.M., Broker TR, Chow LT: Alternative fates of keratinocytes transduced by human papillomavirus type 18 E7 during squamous differentiation. J Virol 2002, 76:2964-2972.
8. McMurray HR, Nguyen D, Westbrook TF, McCance DJ: Biology of human papillomaviruses. Int J Exp Pathol 2001, 82:15-33.
9. Schwarz E, Freese UY, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, Hausen HZ: Structure and Transcription of Human Papillomavirus Sequences in Cervical-Carcinoma Cells. Nature 1985, 314:111-114.
10. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H: A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984, 3:1151-1157.
11. Yee C, Krishnanhewlett I, Baker CC, Schlegel R, Howley PM: Presence and Expression of Human Papillomavirus Sequences in Human Cervical-Carcinoma Cell-Lines. American Journal of Pathology 1985, 119:361-366.
12. Lehn H, Villa LL, Marziona F, Hilgarth M, Hillemans HG, Sauer G: Physical state and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract. J Gen Virol 1988, 69 ( Pt 1):187-196.
13. Ziegert C, Wentzensen N, Vinokurova S, Kisseljov F, Einenkel J, Hoeckel M, von Knebel DM: A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 2003, 22:3977-3984.
14. Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U, Doeberitz MK: Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 2002, 21:419-426.
15. Yu T, Ferber MJ, Cheung TH, Chung TY, Wong YF, Smith DI: The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 2005, 158:27-34.
16. Jeon S, Allen-Hoffmann BL, Lambert PF: Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995, 69:2989-2997.
17. Jeon S, Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 1995, 92:1654-1658.
18. Bernard BA, Bailly C, Lenoir MC, Darmon M, Thierry F, Yaniv M: The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol 1989, 63:4317-4324.
19. Tan SH, Gloss B, Bernard HU: During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Res 1992, 20:251-256.
20. Demeret C, Garcia-Carranca A, Thierry F: Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 2003, 22:168-175.
21. Webster K, Parish J, Pandya M, Stern PL, Clarke AR, Gaston K: The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000, 275:87-94.
22. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P et al.: Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002, 62:472-479.
23. Stunkel W, Huang Z, Tan SH, O'Connor MJ, Bernard HU: Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA. J Virol 2000, 74:2489-2501.
24. Terhune SS, Milcarek C, Laimins LA: Regulation of human papillomavirus type 31 polyadenylation during the differentiation-dependent life cycle. J Virol 1999, 73:7185-7192.
25. Zhao X, Oberg D, Rush M, Fay J, Lambkin H, Schwartz S: A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, ImRNP C1/C2, and polypyrimidine tract binding protein. J Virol 2005, 79:4270-4288.
26. Rossi FM, Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely BT, Blau HM: Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet 1998, 20:389-393.
27. Spicher A, Guicherit OM, Duret L, Aslanian A, Sanjines EM, Denko NC, Giaccia AJ, Blau HM: Highly conserved RNA sequences that are sensors of environmental stress. Mol Cell Biol 1998, 18:7371-7382.
28. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
29. Tan SH, Bartsch D, Schwarz E, Bernard HU: Nuclear matrix attachment regions of human papillomavirus type 16 point toward conservation of these genomic elements in all genital papillomaviruses. J Virol 1998, 72:3610-3622.
30. Furth PA, Choe WT, Rex JH, Byrne JC, Baker CC: Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions. Mol Cell Biol 1994, 14:5278-5289.
31. Collier B, Oberg D, Zhao X, Schwartz S: Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 2002, 76:2739-2752.
32. Koffa MD, Graham SV, Takagaki Y, Manley JL, Clements JB: The human papillomavirus type 16 negative regulatory RNA element interacts with three proteins that act at different posttranscriptional levels. Proc Natl Acad Sci U S A 2000, 97:4677-4682.
33. McPhillips MG, Veerapraditsin T, Cumming SA, Karali D, Milligan SG, Boner W, Morgan IM, Graham SV: SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J Virol 2004, 78:10598-10605.
34. Chen CY, Shyu AB: AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995, 20:465-470.
35. Yang E, van Nimwegen E, Zavolan M, Rajewsky N, Schroeder M, Magnasco M, Darnell JE: Decay rates of human mRNAs: Correlation with functional characteristics and sequence attributes. Genome Research 2003, 13:1863-1872.
36. Zhao C, Tan W, Sokolowski M, Schwartz S: Identification of nuclear and cytoplasmic proteins that interact specifically with an AU-rich, cis-acting inhibitory sequence in the 3' untranslated region of human papillomavirus type 1 late mRNAs. J Virol 1996, 70:3659-3667.
37. Durst M, Glitz D, Schneider A, zur Hansen H: Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992, 189:132-140.
38. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR: Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992, 23:117-128.
39. Collier B, Goobar-Larsson L, Sokolowski M, Schwartz S: Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J Biol Chem 1998, 273:22648-22656.
40. Sokolowski M, Tan W, Jellne M, Schwartz S: mRNA instability elements in the human papillomavirus type 16 L2 coding region. J Virol 1998, 72:1504-1515.